Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Date:2/19/2009

of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology/Medical. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations, and synergistic acquisitions of products and businesses.

For press release and other company information, visit the Watson Pharmaceuticals Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; the difficulty of predicting the timing or outcome of litigation; successful integration of strategic transactions; the ability to recognize the anticipated synergies and benefits of strategic transactions; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting princ
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
2. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
3. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
4. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
5. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
6. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
7. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
9. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
10. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
11. Watson Pharmaceuticals Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (PRWEB) February 26, 2015 In a nested-case ... of the world with a relatively low incidence of liver ... liver cancer, according to a new study published February ... Institute. , Previous studies have reported this association but ... high liver cancer incidence rate, such as Asia. Katherine A. ...
(Date:2/26/2015)... 2015 marks five years of being recognized ... , Orthodontics is a perfect blend of Dr. ... in biomedical engineering, his artistic talent, his extensive training ... allows Dr. Caggiano to create innovative approaches to solve ... Orthodontic Products’ Best of 2012, a national recognition, for ...
(Date:2/26/2015)... February 26, 2015 Beckman Coulter is ... extracellular vesicles and their cargo in cell-to-cell communication,” which ... their relevance for cell-to-cell communication. The webinar is free ... 2015 at 8:00am PT. , Every cell in the ... (EVs) , often called “exosomes” or “microvesicles.” These vesicles ...
(Date:2/26/2015)... “ KnowNote ” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how this application teaches ... , Learning a musical instrument can be difficult. And ... take something they already know and use to learn music ...
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... Chairman J. Robert Baum, Ph.D. is stepping down as ... succeeded by Joseph C. Guyaux, senior vice chairman of ... chief executive officer, PNC Mortgage. Additionally, Highmark Health President ... the chairman of the board of directors of Highmark ...
Breaking Medicine News(10 mins):Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 3Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 4
... 13 The second annual HealthSaver Caffeinated ... emerging health care discount service, found that the ... followed by Seattle, Chicago, New York and Los ... , The least caffeinated cities are Riverside/San ...
... COLUMBIA, Canada, Jan. 13 InNexus Biotechnology ... http://www.ixsbio.com ), a drug development company commercializing the next ... Linking (DXL(TM)) technology, announces the completion of a large ... lead candidate DXL625 (CD20). The Company also announced ...
... from CoSentry, a leading provider of data center ... of the nation,s premier healthcare providers, announced formation ... an enterprise class data center in Papillion, Neb.The ... requirements of Alegent Health,s hospital and clinical applications ...
... Misuse may cause respiratory distress, researchers say; company says ... -- The popular cold remedy Vicks VapoRub may cause ... toddlers, a new study says. , Doctors at Wake ... girl who had developed severe respiratory distress after the ...
... knee ligament reconstruction markets to grow at rates above ... to Millennium Research GroupWALTHAM, Mass., Jan. 13 ... US Markets for Orthopedic Soft Tissue ... for the use of composite materials in both shoulder ...
... Physical ActivitySACRAMENTO, Calif., Jan. 13 New research suggests ... a few clicks away with Dairy Council of California,s ... chronic diseases like type 2 diabetes, heart disease and ... (47.7 percent) engage in at least 30 minutes of ...
Cached Medicine News:Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 2Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 3Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 4Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 5Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 6Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 7Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 8Health News:InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA 2Health News:CoSentry and Alegent Health Announce Collaboration for Construction of an Enterprise-Class Data Center 2Health News:CoSentry and Alegent Health Announce Collaboration for Construction of an Enterprise-Class Data Center 3Health News:CoSentry and Alegent Health Announce Collaboration for Construction of an Enterprise-Class Data Center 4Health News:Vicks VapoRub Linked to Infant Breathing Problems 2Health News:Vicks VapoRub Linked to Infant Breathing Problems 3Health News:Growing Preference for Composite Materials in Shoulder Fixation and Knee Ligament Reconstruction Markets 2Health News:MyFitness Planner Really Moves You 2
(Date:2/26/2015)... 2015  Lyric Pharmaceuticals Inc. today announced the initial ... million. The financing, co-led by RiverVest Venture Partners, Sante ... Venture Partners. Lyric is a clinical-stage ... , M.D., M.B.A., President & Chief Executive Officer and ... In 2014, Lyric closed a seed financing round of ...
(Date:2/26/2015)... 26, 2015 Columbia Laboratories, Inc. (Nasdaq: ... a specialty pharmaceutical company focused on the development ... a Phase II clinical trial for COL-1077, a ... pipelle-directed endometrial biopsy in the second quarter of ... submission feedback from the United States Food and ...
(Date:2/26/2015)... SALT LAKE CITY , Feb. 26, 2015 /PRNewswire/ ... it has launched a "best efforts" follow-on offering of ... unit consists of one share of Series E preferred ... Series E preferred stock will be convertible into four ... will be exercisable into one share of common stock ...
Breaking Medicine Technology:Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3Great Basin Scientific, Inc. Announces Commencement of Public Offering 2Great Basin Scientific, Inc. Announces Commencement of Public Offering 3
... , , ... Designation , SILVER SPRING, Md., Dec. 23 As ... and accessible, the FDA has scheduled a series of workshops about ... the process. The FDA can grant a special status, known as ...
... , ATLANTA, Dec. 23 MiMedx Group, Inc. ... launched its first product, Paradis Vaso Shield(TM). In April ... for use as a cover for vessels following anterior vertebral ... hydrogel product protected by multiple patents and patent applications, as ...
Cached Medicine Technology:FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 11 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Medicine Products: